Masaki Honda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Masaki Honda has a total of 224 co-authors. Here are the top co-authors by number of shared publications:
Yukihiro Inomata
Department of Pediatric Surgery and Transplantation, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan
19 shared publicationsShintaro Hayashida
Department of Pediatric Surgery and Transplantation, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan
17 shared publicationsHidekazu Yamamoto
Department of Transplantation and Pediatric Surgery, Postgraduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan
12 shared publications- Yukihiro Inomata
Department of Surgery, Kumamoto Rosai Hospital, Kumamoto, Japan
11 shared publications Kaori Isono
Department of Pediatric Surgery and Transplantation Kumamoto University Graduate School of Medical Sciences Kumamoto Japan
10 shared publications- Keita Shimata
Department of Pediatric Surgery and Transplantation, Kumamoto University Graduate School of Medical Sciences, Kumamoto, Japan
10 shared publications
Latest Publications
- Open Access
- 18 August 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (8) , e0356246
Integrated transcriptomic and phenotypic analyses reveal spatiotemporal variation in neutrophil Cd14 expression after hepatectomy
Neutrophils are key mediators of both hepatic injury and repair. This study aimed to characterize the spatiotemporal dynamics of Cd14 expression in neutrophils following hepatectomy and to explore its potential role in liver regeneration. We performed an integrated transcriptomic and phenotypic analysis of neutrophil Cd14 expression using bioinformatics and flow cytometry in immune cells isolated from murine livers after 70% partial hepatectomy. Cd14 ranked among the top 10 markers distinguishing activated liver neutrophils from quiescent or stimulated non-hepatic neutrophils. Both Cd14 mRNA and CD14 protein levels were significantly upregulated in hepatic neutrophils, peaking at 24 h after hepatectomy (p = 0.012). Gene set enrichment analysis revealed that Cd14 was associated with Toll-like receptor 4 and IL-6/JAK/STAT3 signaling pathways—both implicated in hepatocyte proliferation—suggesting that Cd14 serves as a marker of a pro-regenerative neutrophil phenotype and represents a potential therapeutic target to enhance liver regeneration following hepatectomy.
- 18 August 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (8) , e0356246
Open AccessIntegrated transcriptomic and phenotypic analyses reveal spatiotemporal variation in neutrophil Cd14 expression after hepatectomy
Neutrophils are key mediators of both hepatic injury and repair. This study aimed to characterize the spatiotemporal dynamics of Cd14 expression in neutrophils following hepatectomy and to explore its potential role in liver regeneration. We performed an integrated transcriptomic and phenotypic analysis of neutrophil Cd14 expression using bioinformatics and flow cytometry in immune cells isolated from murine livers after 70% partial hepatectomy. Cd14 ranked among the top 10 markers distinguishing activated liver neutrophils from quiescent or stimulated non-hepatic neutrophils. Both Cd14 mRNA and CD14 protein levels were significantly upregulated in hepatic neutrophils, peaking at 24 h after hepatectomy (p = 0.012). Gene set enrichment analysis revealed that Cd14 was associated with Toll-like receptor 4 and IL-6/JAK/STAT3 signaling pathways—both implicated in hepatocyte proliferation—suggesting that Cd14 serves as a marker of a pro-regenerative neutrophil phenotype and represents a potential therapeutic target to enhance liver regeneration following hepatectomy.
- 12 August 2026
- Published by Wiley in Pediatric Transplantation
- Vol. 30 (8) , e70426
Long‐Term Outcomes of Living Donor Liver Transplantation in Children With Alagille Syndrome: Results From Vanguard Multicenter Study of International Living Donor Liver Transplantation Group
Background: The morbidity and mortality after living donor liver transplantation (LDLT) in children with Alagille syndrome (AGS) are complex because of the multisystem involvement of the disease. Evidence on long‐term outcomes and donor selection remains limited. Methods: This multicenter retrospective study included 49 pediatric patients with AGS who underwent LDLT between 2001 and 2020 at eight institutions in Japan, Korea, and Turkey. Clinical characteristics, transplant indications, donor selection, posttransplant growth, renal function, and complications were analyzed. Results: The median age at LDLT was 1.1 years. Major indications for transplantation were severe growth failure (91.8%) and advanced liver disease with hepatic dysfunction. Based on donor evaluations, 11% of candidates were excluded due to genetic or anatomical concerns. The 5‐year patient and graft survival rates were 93.7% and 91.5%, respectively. LDLT before 2 years of age was associated with significantly greater catch‐up in height and weight. Long‐term renal deterioration was observed, particularly beyond 15 years after transplantation, and older age at LDLT was an independent predictor of lower long‐term estimated glomerular filtration rate. Cardiac anomalies were manageable with appropriate preoperative evaluation, whereas vasculopathies were observed after adolescence. A history of Kasai portoenterostomy did not significantly affect posttransplant outcomes. Conclusions: LDLT provides excellent short‐ and long‐term outcomes in pediatric AGS. Timely LT may improve growth and preserve renal function before progressive multisystem complications become established. Long‐term surveillance and comprehensive donor evaluation remain essential.
- 12 August 2026
- Published by Wiley in Pediatric Transplantation
- Vol. 30 (8) , e70426
Long‐Term Outcomes of Living Donor Liver Transplantation in Children With Alagille Syndrome: Results From Vanguard Multicenter Study of International Living Donor Liver Transplantation Group
Background: The morbidity and mortality after living donor liver transplantation (LDLT) in children with Alagille syndrome (AGS) are complex because of the multisystem involvement of the disease. Evidence on long‐term outcomes and donor selection remains limited. Methods: This multicenter retrospective study included 49 pediatric patients with AGS who underwent LDLT between 2001 and 2020 at eight institutions in Japan, Korea, and Turkey. Clinical characteristics, transplant indications, donor selection, posttransplant growth, renal function, and complications were analyzed. Results: The median age at LDLT was 1.1 years. Major indications for transplantation were severe growth failure (91.8%) and advanced liver disease with hepatic dysfunction. Based on donor evaluations, 11% of candidates were excluded due to genetic or anatomical concerns. The 5‐year patient and graft survival rates were 93.7% and 91.5%, respectively. LDLT before 2 years of age was associated with significantly greater catch‐up in height and weight. Long‐term renal deterioration was observed, particularly beyond 15 years after transplantation, and older age at LDLT was an independent predictor of lower long‐term estimated glomerular filtration rate. Cardiac anomalies were manageable with appropriate preoperative evaluation, whereas vasculopathies were observed after adolescence. A history of Kasai portoenterostomy did not significantly affect posttransplant outcomes. Conclusions: LDLT provides excellent short‐ and long‐term outcomes in pediatric AGS. Timely LT may improve growth and preserve renal function before progressive multisystem complications become established. Long‐term surveillance and comprehensive donor evaluation remain essential.
- 24 February 2026
- Published by Wiley in Hepatology Research
- Vol. 56 (6) , 1047-1052
Conversion Hepatectomy After New FP Therapy for Malignant Hepatocellular Neoplasm, Not Otherwise Specified: A Case Report
Background: Malignant hepatocellular neoplasm, not otherwise specified (HCN, NOS), is a rare primary liver tumor showing overlapping features of hepatoblastoma and hepatocellular carcinoma. Because of its rarity and histopathologic heterogeneity, the optimal treatment strategy for HCN, NOS remains undefined. Aim and Methods: We report a case of a 20‐year‐old woman with initially unresectable HCN, NOS, who was treated with hepatic arterial infusion chemotherapy using a fine‐powder formulation of cisplatin suspended in Lipiodol combined with continuous 5‐fluorouracil administration (New FP). The therapeutic response was assessed radiologically and serologically after each treatment cycle, and the patient subsequently underwent surgical resection after adequate tumor regression. Results: After eight cycles of New FP, marked tumor shrinkage and a significant decline in tumor markers were achieved, enabling subsequent systemic chemotherapy according to the SIOPEL‐4 regimen. Thereafter, conversion hepatectomy was performed, and histological examination of the resected specimen demonstrated approximately 90% tumor necrosis. The patient has remained disease‐free for 20 months after surgery. Conclusion: This case demonstrates the potential of New FP as an effective hepatic arterial infusion regimen capable of achieving conversion therapy in rare liver malignancies such as HCN, NOS.
- 24 February 2026
- Published by Wiley in Hepatology Research
- Vol. 56 (6) , 1047-1052
Conversion Hepatectomy After New FP Therapy for Malignant Hepatocellular Neoplasm, Not Otherwise Specified: A Case Report
Background: Malignant hepatocellular neoplasm, not otherwise specified (HCN, NOS), is a rare primary liver tumor showing overlapping features of hepatoblastoma and hepatocellular carcinoma. Because of its rarity and histopathologic heterogeneity, the optimal treatment strategy for HCN, NOS remains undefined. Aim and Methods: We report a case of a 20‐year‐old woman with initially unresectable HCN, NOS, who was treated with hepatic arterial infusion chemotherapy using a fine‐powder formulation of cisplatin suspended in Lipiodol combined with continuous 5‐fluorouracil administration (New FP). The therapeutic response was assessed radiologically and serologically after each treatment cycle, and the patient subsequently underwent surgical resection after adequate tumor regression. Results: After eight cycles of New FP, marked tumor shrinkage and a significant decline in tumor markers were achieved, enabling subsequent systemic chemotherapy according to the SIOPEL‐4 regimen. Thereafter, conversion hepatectomy was performed, and histological examination of the resected specimen demonstrated approximately 90% tumor necrosis. The patient has remained disease‐free for 20 months after surgery. Conclusion: This case demonstrates the potential of New FP as an effective hepatic arterial infusion regimen capable of achieving conversion therapy in rare liver malignancies such as HCN, NOS.
- Open Access
- 21 April 2025
- Published by Wiley in Cancer Medicine
- Vol. 14 (8) , e70899
Intravital Imaging of Immune Responses in the Cancer Microenvironment
Background: To date, many types of immune cells have been identified, but their precise role in cancer immunity remains unclear. Understanding the immune responses involved in cancer and the cancer microenvironment is becoming increasingly important for elucidating disease mechanisms. In recent years, the application of intravital imaging in cancer research has provided new insights into the mechanisms of cancer‐specific immune events, including innate and adaptive immunity.Results: In this review, we focus on the emerging role of intravital imaging in cancer research and describe how cancer and immune cells can be observed using intravital imaging in vivo. We also discuss new insights gained by this state‐of‐the‐art technique.Conclusions: Intravital imaging is a relatively new field of research that offers significant advantages, including the ability to directly capture cell–cell interactions, pathophysiology, and immune cell dynamics in the cancer microenvironment in vivo.
- 21 April 2025
- Published by Wiley in Cancer Medicine
- Vol. 14 (8) , e70899
Open AccessIntravital Imaging of Immune Responses in the Cancer Microenvironment
Background: To date, many types of immune cells have been identified, but their precise role in cancer immunity remains unclear. Understanding the immune responses involved in cancer and the cancer microenvironment is becoming increasingly important for elucidating disease mechanisms. In recent years, the application of intravital imaging in cancer research has provided new insights into the mechanisms of cancer‐specific immune events, including innate and adaptive immunity.Results: In this review, we focus on the emerging role of intravital imaging in cancer research and describe how cancer and immune cells can be observed using intravital imaging in vivo. We also discuss new insights gained by this state‐of‐the‐art technique.Conclusions: Intravital imaging is a relatively new field of research that offers significant advantages, including the ability to directly capture cell–cell interactions, pathophysiology, and immune cell dynamics in the cancer microenvironment in vivo.
- 7 August 2023
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 29 (12) , 1292-1303
Hepatic venous outflow obstruction after adult living donor liver transplantation
Hepatic venous outflow obstruction (HVOO) is a rare but critical vascular complication after adult living donor liver transplantation. We categorized HVOOs according to their morphology (anastomotic stenosis, kinking, and intrahepatic stenosis) and onset (early-onset < 3 mo vs. late-onset ≥ 3 mo). Overall, 16/324 (4.9%) patients developed HVOO between 2000 and 2020. Fifteen patients underwent interventional radiology. Of the 16 hepatic venous anastomoses within these 15 patients, 12 were anastomotic stenosis, 2 were kinking, and 2 were intrahepatic stenoses. All of the kinking and intrahepatic stenoses required stent placement, but most of the anastomotic stenoses (11/12, 92%) were successfully managed with balloon angioplasty, which avoided stent placement. Graft survival tended to be worse for patients with late-onset HVOO than early-onset HVOO (40% vs. 69.3% at 5 y, p = 0.162) despite successful interventional radiology. In conclusion, repeat balloon angioplasty can be considered for simple anastomotic stenosis, but stent placement is recommended for kinking or intrahepatic stenosis. Close follow-up is recommended in patients with late-onset HVOO even after successful treatment.
- 7 August 2023
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 29 (12) , 1292-1303
Hepatic venous outflow obstruction after adult living donor liver transplantation
Hepatic venous outflow obstruction (HVOO) is a rare but critical vascular complication after adult living donor liver transplantation. We categorized HVOOs according to their morphology (anastomotic stenosis, kinking, and intrahepatic stenosis) and onset (early-onset < 3 mo vs. late-onset ≥ 3 mo). Overall, 16/324 (4.9%) patients developed HVOO between 2000 and 2020. Fifteen patients underwent interventional radiology. Of the 16 hepatic venous anastomoses within these 15 patients, 12 were anastomotic stenosis, 2 were kinking, and 2 were intrahepatic stenoses. All of the kinking and intrahepatic stenoses required stent placement, but most of the anastomotic stenoses (11/12, 92%) were successfully managed with balloon angioplasty, which avoided stent placement. Graft survival tended to be worse for patients with late-onset HVOO than early-onset HVOO (40% vs. 69.3% at 5 y, p = 0.162) despite successful interventional radiology. In conclusion, repeat balloon angioplasty can be considered for simple anastomotic stenosis, but stent placement is recommended for kinking or intrahepatic stenosis. Close follow-up is recommended in patients with late-onset HVOO even after successful treatment.
- Open Access
- 21 April 2023
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 29 (15) , 2283-2293
Mechanisms of gastrointestinal barrier dysfunction in COVID-19 patients
Mechanisms of gastrointestinal barrier dysfunction in COVID-19 patients
- 21 April 2023
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 29 (15) , 2283-2293
Open AccessMechanisms of gastrointestinal barrier dysfunction in COVID-19 patients
Mechanisms of gastrointestinal barrier dysfunction in COVID-19 patients
- Open Access
- 3 February 2023
- Published by Springer Nature in Inflammation and Regeneration
- Vol. 43 (1) , 1-9
Intravital imaging of immune responses in intestinal inflammation
To date, many kinds of immune cells have been identified, but their precise roles in intestinal immunity remain unclear. Understanding the in vivo behavior of these immune cells and their function in gastrointestinal inflammation, including colitis, inflammatory bowel disease, ischemia–reperfusion injury, and neutrophil extracellular traps, is critical for gastrointestinal research to proceed to the next step. Additionally, understanding the immune responses involved in gastrointestinal tumors and tissue repair is becoming increasingly important for the elucidation of disease mechanisms that have been unknown. In recent years, the application of intravital microscopy in gastrointestinal research has provided novel insights into the mechanisms of intestine-specific events including innate and adaptive immunities. In this review, we focus on the emerging role of intravital imaging in gastrointestinal research and describe how to observe the intestines and immune cells using intravital microscopy. Additionally, we outline novel findings obtained by this new technique.
- 3 February 2023
- Published by Springer Nature in Inflammation and Regeneration
- Vol. 43 (1) , 1-9
Open AccessIntravital imaging of immune responses in intestinal inflammation
To date, many kinds of immune cells have been identified, but their precise roles in intestinal immunity remain unclear. Understanding the in vivo behavior of these immune cells and their function in gastrointestinal inflammation, including colitis, inflammatory bowel disease, ischemia–reperfusion injury, and neutrophil extracellular traps, is critical for gastrointestinal research to proceed to the next step. Additionally, understanding the immune responses involved in gastrointestinal tumors and tissue repair is becoming increasingly important for the elucidation of disease mechanisms that have been unknown. In recent years, the application of intravital microscopy in gastrointestinal research has provided novel insights into the mechanisms of intestine-specific events including innate and adaptive immunities. In this review, we focus on the emerging role of intravital imaging in gastrointestinal research and describe how to observe the intestines and immune cells using intravital microscopy. Additionally, we outline novel findings obtained by this new technique.
- Open Access
- 16 November 2022
- Published by Wiley in Cancer Medicine
- Vol. 12 (4) , 3909-3918
Recent advances in surgical strategies and liver transplantation for hepatoblastoma
Hepatoblastoma (HB) is the most common malignant liver tumor in children. Although the development of treatment strategies with advances in chemotherapy has greatly improved the prognosis of HB, surgical resection and liver transplantation still play a vital role in the treatment of HB. In recent years, technological innovations have led to the development of new surgical approaches for HB. In this review, we describe the latest research on the surgical management of HB, including new imaging technologies, minimally invasive approaches, and the application of associating liver partition portal vein ligation for staged hepatectomy. We also discuss the current role of liver transplantation, use of ante‐situm or ex‐situ liver resection with auto‐transplantation, and management of metastatic HB.
- 16 November 2022
- Published by Wiley in Cancer Medicine
- Vol. 12 (4) , 3909-3918
Open AccessRecent advances in surgical strategies and liver transplantation for hepatoblastoma
Hepatoblastoma (HB) is the most common malignant liver tumor in children. Although the development of treatment strategies with advances in chemotherapy has greatly improved the prognosis of HB, surgical resection and liver transplantation still play a vital role in the treatment of HB. In recent years, technological innovations have led to the development of new surgical approaches for HB. In this review, we describe the latest research on the surgical management of HB, including new imaging technologies, minimally invasive approaches, and the application of associating liver partition portal vein ligation for staged hepatectomy. We also discuss the current role of liver transplantation, use of ante‐situm or ex‐situ liver resection with auto‐transplantation, and management of metastatic HB.
- Open Access
- 8 February 2022
- Published by Wiley in Cancer Medicine
- Vol. 11 (6) , 1441-1453
IL‐34 in hepatoblastoma cells potentially promote tumor progression via autocrine and paracrine mechanisms
Hepatoblastoma is the most common pediatric liver tumor, but little research has been done on the role of macrophages in hepatoblastoma. The purpose of this study was to gain insight into potential roles for macrophages in hepatoblastoma. Paraffin‐embedded specimens from 56 patients who underwent surgical resection were examined with immunohistochemical staining for the macrophage‐specific markers, Iba1 and CD163. Significant differences were seen among histological subtypes. Significantly increased numbers of macrophages were detected in embryonal components compared to fetal components in the mixed epithelial type. In vitro studies using human monocyte‐derived macrophages and two hepatoblastoma cell lines (HepG2 and Huh6) were performed. Conditioned medium from these cell lines induced increased CD163 expression in macrophages. Direct co‐culture with macrophages induced tumor cell proliferation via induction of protumor cytokine secretion from macrophages. Direct co‐culture with macrophages also induced interleukin (IL)‐34 overexpression by Huh6 cells via Brd4 signaling. IL‐34 overexpression promoted tumor cell proliferation and chemoresistance. High IL‐34 and Brd4 expression was detected in embryonal components, which have potentially higher proliferation activity than fetal components. In conclusion, IL‐34 expression in embryonal components may induce macrophage chemotaxis in a paracrine manner, and tumor cell proliferation and chemoresistance in an autocrine manner. IL‐34 is a potential therapeutic target for hepatoblastoma.
- 8 February 2022
- Published by Wiley in Cancer Medicine
- Vol. 11 (6) , 1441-1453
Open AccessIL‐34 in hepatoblastoma cells potentially promote tumor progression via autocrine and paracrine mechanisms
Hepatoblastoma is the most common pediatric liver tumor, but little research has been done on the role of macrophages in hepatoblastoma. The purpose of this study was to gain insight into potential roles for macrophages in hepatoblastoma. Paraffin‐embedded specimens from 56 patients who underwent surgical resection were examined with immunohistochemical staining for the macrophage‐specific markers, Iba1 and CD163. Significant differences were seen among histological subtypes. Significantly increased numbers of macrophages were detected in embryonal components compared to fetal components in the mixed epithelial type. In vitro studies using human monocyte‐derived macrophages and two hepatoblastoma cell lines (HepG2 and Huh6) were performed. Conditioned medium from these cell lines induced increased CD163 expression in macrophages. Direct co‐culture with macrophages induced tumor cell proliferation via induction of protumor cytokine secretion from macrophages. Direct co‐culture with macrophages also induced interleukin (IL)‐34 overexpression by Huh6 cells via Brd4 signaling. IL‐34 overexpression promoted tumor cell proliferation and chemoresistance. High IL‐34 and Brd4 expression was detected in embryonal components, which have potentially higher proliferation activity than fetal components. In conclusion, IL‐34 expression in embryonal components may induce macrophage chemotaxis in a paracrine manner, and tumor cell proliferation and chemoresistance in an autocrine manner. IL‐34 is a potential therapeutic target for hepatoblastoma.